Simon Pieter Jochems

Simon Pieter Jochems

Auto-generated profile, based on publicly available information

Simon Pieter Jochems

Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2018 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SJSimon P. Jochems
Simon P. Jochems
FMFernando Marcon
Fernando Marcon
BCBeatriz F. Carniel
Beatriz F. Carniel
MHMark Holloway
Mark Holloway
EMElena Mitsi
Elena Mitsi
DFDaniela M. Ferreira
Daniela M. Ferreira

17 February 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MLMarijke C. C. Langenberg
Marijke C. C. Langenberg
MHMarie-Astrid Hoogerwerf
Marie-Astrid Hoogerwerf
JKJan Pieter R. Koopman
Jan Pieter R. Koopman
JJJacqueline J. Janse
Jacqueline J. Janse
JOJanneke Kos-Van Oosterhoud
Janneke Kos-Van Oosterhoud
MRMeta Roestenberg
Meta Roestenberg

22 December 2021 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
ARAnna H. E. Roukens
Anna H. E. Roukens
CPCilia R. Pothast
Cilia R. Pothast
MKMarion König
Marion König
WHWesley Huisman
Wesley Huisman
TDTim Dalebout
Tim Dalebout
SJSimon P. Jochems
Simon P. Jochems

21 December 2017 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
SJSimon P. Jochems
Simon P. Jochems
JWJeffrey N. Weiser
Jeffrey N. Weiser
RMRichard Malley
Richard Malley
DFDaniela M. Ferreira
Daniela M. Ferreira
Colonization of the human nasopharynx by pneumococcus is extremely common and is both the primary reservoir for transmission and a prerequisite for disease. Current vaccines targeting the polysaccharide capsule effectively prevent colonization, conferring herd protection within vaccinated communities. However, these vaccines cover only a subset of all circulating pneumococcal strains, and serotype replacement has been observed. Given the success of pneumococcal conjugate vaccine (PCV) in preventing colonization in unvaccinated adults within vaccinated communities, reducing nasopharyngeal colonization has become an outcome of interest for novel vaccines. Here, we discuss the immunological mechanisms that control nasopharyngeal colonization, with an emphasis on findings from human studies. Increased understanding of these immunological mechanisms is required to identify correlates of protection against colonization that will facilitate the early testing and design of novel vaccines.

5 July 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
WPWouter A. A. de Steenhuijsen Piters
Wouter A. A. de Steenhuijsen Piters
SJSimon P. Jochems
Simon P. Jochems
EMElena Mitsi
Elena Mitsi
JRJamie Rylance
Jamie Rylance
SPSherin Pojar
Sherin Pojar
DBDebby Bogaert
Debby Bogaert
Streptococcus pneumoniae is the main bacterial pathogen involved in pneumonia. Pneumococcal acquisition and colonization density is probably affected by viral co-infections, the local microbiome composition and mucosal immunity. Here, we report the interactions between live-attenuated influenza vaccine (LAIV), successive pneumococcal challenge, and the healthy adult nasal microbiota and mucosal immunity using an experimental human challenge model. Nasal microbiota profiles at baseline are associated with consecutive pneumococcal carriage outcome (non-carrier, low-dense and high-dense pneumococcal carriage), independent of LAIV co-administration. Corynebacterium/Dolosigranulum-dominated profiles are associated with low-density colonization. Lowest rates of natural viral co-infection at baseline and post-LAIV influenza replication are detected in the low-density carriers. Also, we detected the fewest microbiota perturbations and mucosal cytokine responses in the low-density carriers compared to non-carriers or high-density carriers. These results indicate that the complete respiratory ecosystem affects pneumococcal behaviour following challenge, with low-density carriage representing the most stable ecological state.

20 January 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SJSimon P Jochems
Simon P Jochems
KPKatherine Piddock
Katherine Piddock
JRJamie Rylance
Jamie Rylance
HAHugh Adler
Hugh Adler
BCBeatriz F Carniel
Beatriz F Carniel
DFDaniela M Ferreira
Daniela M Ferreira
The morbidity and mortality related to respiratory tract diseases is enormous, with hundreds of millions of individuals afflicted and four million people dying each year. Understanding the immunological processes in the mucosa that govern outcome following pathogenic encounter could lead to novel therapies. There is a need to study responses at mucosal surfaces in humans for two reasons: (i) Immunological findings in mice, or other animals, often fail to translate to humans. (ii) Compartmentalization of the immune system dictates a need to study sites where pathogens reside. In this manuscript, we describe two novel non-invasive nasal mucosal microsampling techniques and their use for measuring immunological parameters: 1) using nasal curettes to collect cells from the inferior turbinate and; 2) absorptive matrices to collect nasal lining fluid. Both techniques were well tolerated and yielded reproducible and robust data. We demonstrated differences in immune populations and activation state in nasal mucosa compared to blood as well as compared to nasopharyngeal lumen in healthy adults. We also found superior cytokine detection with absorptive matrices compared to nasal wash. These techniques are promising new tools that will facilitate studies of the immunological signatures underlying susceptibility and resistance to respiratory infections.